Systemic amyloidosis

The Lancet

Volumn 387, Issue 10038, 2016, Pages 2641-2654

  Wechalekar, Ashutosh D ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; IMMUNOMODULATING AGENT; PREALBUMIN; TRACER;

BONE SCINTISCANNING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; COLLAGEN FIBRIL; EARLY DIAGNOSIS; FAMILIAL AMYLOIDOSIS; HEART AMYLOIDOSIS; HISTOLOGY; HUMAN; MASS SPECTROMETRY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SURVIVAL; AMYLOIDOSIS;

AMYLOIDOSIS; HUMANS;

EID: 84978818521     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01274-X     Document Type: Review

References (150)

1. 1 Lachmann, HJ, Hawkins, PN, Systemic amyloidosis. Curr Opin Pharmacol 6 (2006), 214–220.
2. 2 Merlini, G, Systemic amyloidosis: are we moving ahead?. Neth J Med 62 (2004), 104–105.
3. 3 Sipe, JD, Benson, MD, Buxbaum, JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21 (2014), 221–224.
4. 4 Esplin, BL, Gertz, MA, Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol 38 (2013), 53–96.
5. 5 Kyle, RA, Linos, A, Beard, CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 (1992), 1817–1822.
6. 6 Pinney, JH, Smith, CJ, Taube, JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 161 (2013), 525–532.
7. 7 Hemminki, K, Li, X, Försti, A, Sundquist, J, Sundquist, K, Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health, 12, 2012, 974.
8. 8 Valleix, S, Gillmore, JD, Bridoux, F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 366 (2012), 2276–2283.
9. 9 Wechalekar, AD, Gillmore, JD, Foard, D, et al. 25 years of systemic amyloidosis. Hazenberg, PB, (eds.) International amyloidosis symposium, 2012, Netherlands, Groningen.
10. 10 Tanskanen, M, Peuralinna, T, Polvikoski, T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40 (2008), 232–239.
11. 11 Benson, MD, James, S, Scott, K, Liepnieks, JJ, Kluve-Beckerman, B, Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int 74 (2008), 218–222.
12. 12 Murphy, C, Wang, S, Kestler, D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis. Amyloid 18:suppl 1 (2011), 223–225.
13. 13 Murphy, CL, Wang, S, Kestler, D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 56 (2010), 1100–1107.
14. 14 Larsen, CP, Walker, PD, Weiss, DT, Solomon, A, Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 77 (2010), 816–819.
15. 15 Sousa, A, Coelho, T, Barros, J, Sequeiros, J, Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 60 (1995), 512–521.
16. 16 Holmgren, G, Costa, PM, Andersson, C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 31 (1994), 351–354.
17. 17 Hellman, U, Alarcon, F, Lundgren, HE, Suhr, OB, Bonaiti-Pellie, C, Plante-Bordeneuve, V, Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15 (2008), 181–186.
18. 18 Reilly, MM, Staunton, H, Harding, AE, Familial amyloid polyneuropathy (TTR ala 60) in North West Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 59 (1995), 45–49.
19. 19 Jacobson, DR, Pastore, RD, Yaghoubian, R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336 (1997), 466–473.
20. 20 Sawaya, MR, Sambashivan, S, Nelson, R, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447 (2007), 453–457.
21. 21 Bonar, L, Cohen, AS, Skinner, MM, Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 131 (1969), 1373–1375.
22. 22 Glenner, GG, Terry, WD, Characterization of amyloid. Annu Rev Med 25 (1974), 131–135.
23. 23 Sunde, M, Serpell, LC, Bartlam, M, Fraser, PE, Pepys, MB, Blake, CC, Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273 (1997), 729–739.
24. 24 Pepys, MB, Rademacher, TW, Amatayakul-Chantler, S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 91 (1994), 5602–5606.
25. 25 Tan, SY, Pepys, MB, Amyloidosis. Histopathology 25 (1994), 403–414.
26. 26 Dember, LM, Hawkins, PN, Hazenberg, BP, et al., the Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356 (2007), 2349–2360.
27. 27 Bodin, K, Ellmerich, S, Kahan, MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468 (2010), 93–97.
28. 28 Falk, RH, Diagnosis and management of the cardiac amyloidoses. Circulation 112 (2005), 2047–2060.
29. 29 Merlini, G, CyBorD: stellar response rates in AL amyloidosis. Blood 119 (2012), 4343–4345.
30. 30 Pinney, JH, Whelan, CJ, Petrie, A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc, 2, 2013, e000098.
31. 31 Lachmann, HJ, Goodman, HJ, Gilbertson, JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 (2007), 2361–2371.
32. 32 Liao, R, Jain, M, Teller, P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104 (2001), 1594–1597.
33. 33 Shi, J, Guan, J, Jiang, B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107 (2010), 4188–4193.
34. 34 Gillmore, JD, Lachmann, HJ, Rowczenio, D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20 (2009), 444–451.
35. 35 Sattianayagam, PT, Gibbs, SD, Rowczenio, D, et al. Hereditary lysozyme amyloidosis—phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 272 (2012), 36–44.
36. 36 Reilly, MM, Staunton, H, Peripheral nerve amyloidosis. Brain Pathol 6 (1996), 163–177.
37. 37 Sekijima, Y, Uchiyama, S, Tojo, K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 42 (2011), 1785–1791.
38. 38 Gertz, MA, Comenzo, R, Falk, RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79 (2005), 319–328.
39. 39 Dispenzieri, A, Gertz, MA, Kyle, RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22 (2004), 3751–3757.
40. 40 Sipe, JD, Benson, MD, Buxbaum, JN, et al., the Nomenclature Committee of the International Society of Amyloidosis. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19 (2012), 167–170.
41. 41 Nilsson, KP, Ikenberg, K, Aslund, A, et al. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol 176 (2010), 563–574.
42. 42 Foli, A, Palladini, G, Caporali, R, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 18:suppl 1 (2011), 80–82.
43. 43 Schönland, SO, Hegenbart, U, Bochtler, T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119 (2012), 488–493.
44. 44 Arbustini, E, Morbini, P, Verga, L, et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 4 (1997), 157–170.
45. 45 Palladini, G, Russo, P, Bosoni, T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55 (2009), 499–504.
46. 46 Lachmann, HJ, Gallimore, R, Gillmore, JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122 (2003), 78–84.
47. 47 Deshmukh, M, Elderfield, K, Rahemtulla, A, Naresh, KN, Immunophenotype of neoplastic plasma cells in AL amyloidosis. J Clin Pathol 62 (2009), 724–730.
48. 48 Paiva, B, Vidriales, MB, Pérez, JJ, et al. the GEM (Grupo Español de MM) Cooperative Study Ggroup, the PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 94 (2009), 1599–1602.
49. 49 Kyle, RA, Durie, BG, Rajkumar, SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24 (2010), 1121–1127.
50. 50 Hawkins, PN, Lavender, JP, Pepys, MB, Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323 (1990), 508–513.
51. 51 Buss, SJ, Emami, M, Mereles, D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 60 (2012), 1067–1076.
52. 52 Selvanayagam, JB, Hawkins, PN, Paul, B, Myerson, SG, Neubauer, S, Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50 (2007), 2101–2110.
53. 53 Maceira, AM, Joshi, J, Prasad, SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005), 186–193.
54. 54 Mekinian, A, Lions, C, Leleu, X, et al., the Lille Amyloidosis Study Group. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 123 (2010), 864–868.
55. 55 Banypersad, SM, Sado, DM, Flett, AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6 (2013), 34–39.
56. 56 Bokhari, S, Castaño, A, Pozniakoff, T, Deslisle, S, Latif, F, Maurer, MS, (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6 (2013), 195–201.
57. 57 Chen, W, Dilsizian, V, Molecular imaging of amyloidosis: will the heart be the next target after the brain?. Curr Cardiol Rep 14 (2012), 226–233.
58. 58 Castano, A, Bokhari, S, Brannagan, TH 3rd, Wynn, J, Maurer, MS, Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid 19 (2012), 41–46.
59. 59 Rapezzi, C, Quarta, CC, Guidalotti, PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 38 (2011), 470–478.
60. 60 Rapezzi, C, Guidalotti, P, Salvi, F, Riva, L, Perugini, E, Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 51 (2008), 1509–1510.
61. 61 Perugini, E, Guidalotti, PL, Salvi, F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46 (2005), 1076–1084.
62. 62 Hutt, DF, Quigley, AM, Page, J, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 15 (2014), 1289–1298.
63. 63 Hongo, M, Urushibata, K, Kai, R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 144 (2002), 122–129.
64. 64 Lekakis, J, Dimopoulos, MA, Prassopoulos, V, et al. Myocardial adrenergic denervation in patients with primary (AL) amyloidosis. Amyloid 10 (2003), 117–120.
65. 65 Antoni, G, Lubberink, M, Estrada, S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 54 (2013), 213–220.
66. 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 41 (2014), 1652–1662.
67. 67 Wechalekar, A, Schonland, SO, Kastritis, E, et al. European collaborative study of treatment outcomes in 347 patients with systemic AL amyloidosis with Mayo stage III disease. Blood, 118, 2011, 995.
68. 68 Palladini, G, Barassi, A, Klersy, C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116 (2010), 3426–3430.
69. 69 Kristen, AV, Giannitsis, E, Lehrke, S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116 (2010), 2455–2461.
70. 70 Wechalekar, AD, Schonland, SO, Kastritis, E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121 (2013), 3420–3427.
71. 71 Dispenzieri, A, Lacy, MQ, Katzmann, JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107 (2006), 3378–3383.
72. 72 Wechalekar, A, Wassef, N, Lachmann, H, et al. High early mortality and poor outcomes for patients with AL amyloidosis presenting with high serum free light chains - a new risk stratification model. Haematologica, 94, 2009, 222.
73. 73 Kourelis, TV, Kumar, SK, Gertz, MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 31 (2013), 4319–4324.
74. 74 Palladini, G, Hegenbart, U, Milani, P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124 (2014), 2325–2332.
75. 75 Comenzo, RL, Reece, D, Palladini, G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26 (2012), 2317–2325.
76. 76 Palladini, G, Dispenzieri, A, Gertz, MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30 (2012), 4541–4549.
77. 77 Gertz, MA, Dispenzieri, A, Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology 26 (2012), 152–161.
78. 78 Dispenzieri, A, Seenithamby, K, Lacy, MQ, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 48 (2013), 1302–1307.
79. 79 Bochtler, T, Hegenbart, U, Heiss, C, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 117 (2011), 3809–3815.
80. 80 Gertz, MA, Greipp, PR, Kyle, RA, Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med 118 (1991), 33–39.
81. 81 Palladini, G, Perfetti, V, Obici, L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103 (2004), 2936–2938.
82. 82 Palladini, G, Russo, P, Nuvolone, M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110 (2007), 787–788.
83. 83 Wechalekar, AD, Goodman, HJB, Lachmann, HJ, Offer, M, Hawkins, PN, Gillmore, JD, Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109 (2007), 457–464.
84. 84 Reece, DE, Hegenbart, U, Sanchorawala, V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 118 (2011), 865–873.
85. 85 Dispenzieri, A, Lacy, MQ, Zeldenrust, SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109 (2007), 465–470.
86. 86 Jaccard, A, Moreau, P, Leblond, V, et al., the Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (2007), 1083–1093.
87. 87 Cibeira, MT, Sanchorawala, V, Seldin, DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118 (2011), 4346–4352.
88. 88 Landau, H, Hassoun, H, Rosenzweig, MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light chain amyloidosis. Leukemia 27 (2013), 823–828.
89. 89 Venner, CP, Lane, T, Foard, D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119 (2012), 4387–4390.
90. 90 Kumar, SK, Hayman, SR, Buadi, FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119 (2012), 4860–4867.
91. 91 Moreau, P, Jaccard, A, Benboubker, L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 116 (2010), 4777–4782.
92. 92 Dispenzieri, A, Buadi, F, Laumann, K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119 (2012), 5397–5404.
93. 93 Merlini, G, Sanchorawala, V, Zonder, JA, et al. MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study. Blood, 120, 2012, 731 (abstr).
94. 94 Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 46 (2011), 970–975.
95. 95 Gertz, MA, Lacy, MQ, Dispenzieri, A, et al. Refinement in patient selection to reduce treatment-related mortality from SCT in amyloidosis. Bone Marrow Transplant 48 (2013), 557–561.
96. 96 Comenzo, RL, Gertz, MA, Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99 (2002), 4276–4282.
97. 97 Sanchorawala, V, Seldin, DC, Magnani, B, Skinner, M, Wright, DG, Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36 (2005), 597–600.
98. 98 Skinner, M, Sanchorawala, V, Seldin, DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140 (2004), 85–93.
99. 99 Landau, H, Hassoun, H, Rosenzweig, MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 27 (2013), 823–828.
100. 100 Sanchorawala, V, Brauneis, D, Shelton, AC, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for AL amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant, 2015, 10.1016/j.bbmt.2015.04.001 published online April 6.
101. 101 Richardson, PG, Barlogie, B, Berenson, J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003), 2609–2617.
102. 102 Dimopoulos, MA, Kastritis, E, Bortezomib for AL amyloidosis: moving forward. Blood 118 (2011), 827–828.
103. 103 Reece, DE, Sanchorawala, V, Hegenbart, U, et al., the VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114 (2009), 1489–1497.
104. 104 Wechalekar, AD, Lachmann, HJ, Offer, M, Hawkins, PN, Gillmore, JD, Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93 (2008), 295–298.
105. 105 Kastritis, E, Wechalekar, AD, Dimopoulos, MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28 (2010), 1031–1037.
106. 106 Mikhael, JR, Schuster, SR, Jimenez-Zepeda, VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119 (2012), 4391–4394.
107. 107 Sanchorawala, V, Finn, KT, Fennessey, S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 116 (2010), 1990–1991.
108. 108 Kastritis, E, Terpos, E, Roussou, M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 119 (2012), 5384–5390.
109. 109 Palladini, G, Russo, P, Milani, P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 98 (2013), 433–436.
110. 110 Venner, CP, Gillmore, JD, Sachchithanantham, S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 8 (2014), 2304–2310.
111. 111 Lane, T, Loeffler, JM, Rowczenio, DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65 (2013), 1116–1121.
112. 112 Pinney, JH, Lachmann, HJ, Systemic, AA, Systemic AA amyloidosis. Subcell Biochem 65 (2012), 541–564.
113. 113 Obici, L, Merlini, G, AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly, 142, 2012, w13580.
114. 114 Nakamura, T, Higashi, S, Tomoda, K, Tsukano, M, Shono, M, Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 29 (2010), 1395–1401.
115. 115 Pettersson, T, Kantonen, J, Matikainen, S, Repo, H, Setting up TRAPS. Ann Med 44 (2012), 109–118.
116. 116 Obici, L, Meini, A, Cattalini, M, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70 (2011), 1511–1512.
117. 117 Kuemmerle-Deschner, JB, Hachulla, E, Cartwright, R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70 (2011), 2095–2102.
118. 118 Lachmann, HJ, Kone-Paut, I, Kuemmerle-Deschner, JB, et al., the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 (2009), 2416–2425.
119. 119 Kisilevsky, R, Szarek, WA, Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neuroscience 19 (2002), 45–50.
120. 120 Kisilevsky, R, Ancsin, JB, Szarek, WA, Petanceska, S, Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14 (2007), 21–32.
121. 121 Sattianayagam, P, Gibbs, SD, Pinney, JH, et al. The role of liver transplantation in hereditary non-neuropathic systemic amyloidosis. Gastroenterology, 140, 2011, S-963 (abstr).
122. 122 de Carvalho, M, Conceicao, I, Bentes, C, Luis, ML, Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 9 (2002), 126–133.
123. 123 Stangou, AJ, Hawkins, PN, Heaton, ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 66 (1998), 229–233.
124. 124 Ericzon, BG, Larsson, M, Wilczek, HE, Domino liver transplantation: risks and benefits. Transplant Proc 40 (2008), 1130–1131.
125. 125 Pradotto, L, Franchello, A, Milesi, A, et al. Amyloid polyneuropathy following domino liver transplantation. Muscle Nerve 45 (2012), 918–919.
126. 126 Antonini, TM, Lozeron, P, Lacroix, C, et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant 13 (2013), 2734–2738.
127. 127 Abdelfatah, MM, Hayman, SR, Gertz, MA, Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid 21 (2014), 136–137.
128. 128 Hamour, IM, Lachmann, HJ, Goodman, HJ, et al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant 8 (2008), 1056–1059.
129. 129 Fuchs, U, Zittermann, A, Suhr, O, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant 5 (2005), 1159–1162.
130. 130 Stangou, AJ, Banner, NR, Hendry, BM, et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115 (2010), 2998–3007.
131. 131 Gillmore, JD, Lachmann, HJ, Wechalekar, A, Hawkins, PN, Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood, 115, 2010, 4313.
132. 132 Dubrey, SW, Comenzo, RL, Amyloid diseases of the heart: current and future therapies. QJM 105 (2012), 617–631.
133. 133 Rowczenio, D, Dogan, A, Theis, JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179 (2011), 1978–1987.
134. 134 Gillmore, JD, Stangou, AJ, Lachmann, HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 6 (2006), 2342–2347.
135. 135 Johnson, SM, Connelly, S, Fearns, C, Powers, ET, Kelly, JW, The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421 (2012), 185–203.
136. 136 Coelho, T, Maia, LF, Martins da Silva, A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79 (2012), 785–792.
137. 137 Kolstoe, SE, Mangione, PP, Bellotti, V, et al. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA 107 (2010), 20483–20488.
138. 138 Sekijima, Y, Dendle, MA, Kelly, JW, Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13 (2006), 236–249.
139. 139 Miller, SR, Sekijima, Y, Kelly, JW, Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84 (2004), 545–552.
140. 140 Berk, JL, Suhr, OB, Obici, L, et al., the Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
141. 141 Adams, D, Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 6 (2013), 129–139.
142. 142 Coelho, T, Adams, D, Silva, A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369 (2013), 819–829.
143. 143 Solomon, A, Weiss, DT, Wall, JS, Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res 9 (2003), 3831S–3838S.
144. 144 Hrncic, R, Wall, J, Wolfenbarger, DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 157 (2000), 1239–1246.
145. 145 Wall, JS, Kennel, SJ, Stuckey, AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 116 (2010), 2241–2244.
146. 146 Wall, JS, Kennel, SJ, Williams, A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One, 7, 2012, e52686.
147. 147 Tennent, GA, Lovat, LB, Pepys, MB, Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92 (1995), 4299–4303.
148. 148 Pepys, MB, Herbert, J, Hutchinson, WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002), 254–259.
149. 149 Gillmore, JD, Tennent, GA, Hutchinson, WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148 (2010), 760–767.
150. 150 Richards, DM, Cookson, LM, Berges, AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid p component. N Engl J Med 373 (2015), 1106–1114.